Cost-effectiveness of broadly neutralizing antibodies for HIV prophylaxis for infants born in settings with high HIV burdens
PLoS ONE,
Journal Year:
2025,
Volume and Issue:
20(3), P. e0318940 - e0318940
Published: March 19, 2025
Background
Approximately
130
000
infants
acquire
HIV
annually
despite
global
maternal
antiretroviral
therapy
scale-up.
We
evaluated
the
potential
clinical
impact
and
cost-effectiveness
of
offering
long-acting,
anti-HIV
broadly
neutralizing
antibody
(bNAb)
prophylaxis
to
in
three
distinct
settings.
Methods
simulated
Côte
d’Ivoire,
South
Africa,
Zimbabwe
using
Cost-Effectiveness
Preventing
AIDS
Complications-Pediatric
(CEPAC-P)
model.
modeled
strategies
a
three-bNAb
combination
addition
WHO-recommended
standard-of-care
oral
infants:
a)
with
known,
WHO-defined
high-risk
exposure
at
birth
(
HR-HIVE
);
b)
known
HIVE
or
c)
without
ALL
).
Modeled
received
1-dose
,
2-doses
Extended
(every
3
months
through
18
months)
bNAb
dosing.
Base
case
model
inputs
included
70%
efficacy
(sensitivity
analysis
range:
10–100%),
3-month
duration/dosing
interval
(1–6
months),
$20/dose
cost
($5–$100/dose).
Outcomes
pediatric
infections,
life
expectancy,
lifetime
HIV-related
costs,
incremental
ratios
(ICERs,
US$/year-of-life-saved
[YLS],
assuming
≤
50%
GDP
per
capita
threshold).
Findings
The
base
projects
that
targeting
would
prevent
7–26%
10–42%
additional
respectively,
compared
alone,
ranging
by
dosing
approach.
HIVE-Extended
be
cost-effective
(cost-saving
standard-of-care)
d’Ivoire
Zimbabwe;
ALL-Extended
Africa
(ICER:
$882/YLS).
BNAb
result
greater
costs
smaller
expectancy
gains
than
.
Throughout
most
efficacies
sensitivity
analyses,
Zimbabwe,
Africa.
Interpretation
Adding
long-acting
bNAbs
current
cost-effective,
plausible
costs.
target
population
vary
setting,
largely
driven
antenatal
prevalence
postpartum
incidence.
Language: Английский
Manufacturing innovation is essential for monoclonal antibody affordability and access
Nature Reviews Bioengineering,
Journal Year:
2025,
Volume and Issue:
unknown
Published: April 17, 2025
Language: Английский
Modeling and Optimization of Recombinant Tocilizumab Production From Pichia pastoris Using Response Surface Methodology and Artificial Neural Network
Biotechnology and Bioengineering,
Journal Year:
2025,
Volume and Issue:
unknown
Published: May 15, 2025
ABSTRACT
This
study
has
demonstrated
the
optimization
of
defined
medium
that
significantly
enhanced
production
recombinant
monoclonal
antibody
(mAb)
Tocilizumab
(TCZ)
as
full‐length
and
Fab
fragment
from
Pichia
pastoris
.
Out
four
tested
media,
FM22
was
found
to
be
suitable
for
growth
strains
yield.
Among
various
carbon
nitrogen
sources
tested,
mannitol
glycine,
respectively,
were
TCZ.
Similarly,
sorbitol
ammonium
sulfate
sources,
Fab.
The
components
influenced
TCZ
mannitol,
histidine,
K
2
SO
4
sorbitol,
sulfate,
KH
PO
,
CaSO
.2H
O
Fab,
using
a
two‐level
factorial
Plackett‐Burman
design.
screened
optimized
response
surface
methodology
(Box‐Behnken
Design).
Artificial
neural
network
(ANN)
models
combined
with
genetic
algorithms
(GA)
further
improved
predictions
showed
remarkable
impact
on
mAb
in
P.
Under
optimal
levels
components,
determined
0.35
mg/L
0.42
g/L,
shake‐flask
culture.
yield
batch
reactor
(2‐L
culture)
0.44
0.45
at
components.
overall
increased
yields
observed
3.8
2.9‐folds
respectively.
Language: Английский
Peptide-Based Regulation of TNF-α-Mediated Cytotoxicity
Betül Zehra Temur,
No information about this author
Ahmet Can Timuçin,
No information about this author
A. Emin Atik
No information about this author
et al.
Biomolecules,
Journal Year:
2025,
Volume and Issue:
15(4), P. 559 - 559
Published: April 10, 2025
Tumor
necrosis
factor
alpha
(TNF-α)
is
a
pro-inflammatory
cytokine
associated
with
TNF
receptor
1
(TNFR1)
and
2
(TNFR2),
which
play
important
roles
in
several
inflammatory
diseases.
There
growing
interest
developing
alternative
molecules
that
can
be
used
as
blockers.
In
this
study,
we
focused
on
TNF-α-,
TNFR1-,
TNFR2-mimicking
peptides
to
inhibit
TNF-α
binding
various
ways.
Six
(OB1,
OB2,
OB5,
OB6,
OB7,
OB8)
were
developed
bind
TNFR1,
TNFR2,
TNF-α.
OB1
OB2
bound
lower
Kd
values
of
300
46.7
nM,
respectively,
compared
previously
published
sequences.
These
synthetic
directly
indirectly
inhibited
vitro
without
cytotoxicity
L929
cells,
significantly
apoptosis
the
presence
hTNF-α.
Peptides
study
may
prove
useful
for
therapeutic
inhibition
Language: Английский
Safety, Efficacy, and Effectiveness of Maternal Vaccination against Respiratory Infections in Young Infants
Nisha Makan-Murphy,
No information about this author
Shabir A. Madhi,
No information about this author
Ziyaad Dangor
No information about this author
et al.
Seminars in Respiratory and Critical Care Medicine,
Journal Year:
2024,
Volume and Issue:
unknown
Published: Dec. 21, 2024
Lower
respiratory
tract
infection
(LRTI)
is
a
major
cause
of
neonatal
morbidity
and
mortality
worldwide.
Maternal
vaccination
an
effective
strategy
in
protecting
young
infants
from
LRTI,
particularly
the
first
few
months
after
birth
when
infant
most
vulnerable,
primary
childhood
vaccinations
have
not
been
administered.
Additionally,
maternal
protects
mother
illness
during
pregnancy
postnatal
period,
developing
fetus
adverse
outcomes
such
as
stillbirth
prematurity.
In
this
paper,
we
review
safety,
efficacy,
effectiveness
vaccines
against
LRTIs,
pertussis,
influenza,
coronavirus
disease
2019,
syncytial
virus.
Language: Английский